Thomas Kipps

29PUBLICATIONS
152CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Oct 02, 2026
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|May 06, 2026
Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis.

|Nov 06, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Kerry A Rogers, Pearlly Yan, Ian W Flinn

|Apr 28, 2025
Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.

Md Kamrul Hasan, George F Widhopf Ii, Emanuela M Ghia

|Feb 19, 2025
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.

Recep Bayraktar, Yitao Tang, Mihnea P Dragomir

Pageof 5

Frequent Collaborators

6 joint publications

Emanuela M Ghia

4 joint publications

William G Wierda

3 joint publications

Suping Zhang

3 joint publications

Donna S Neuberg